Toward a Risk-Based Assessment of the Adult Cancer Survivor: Late Effects of Chemotherapy

References

• Ganz PA. Cancer survivors: a physician's perspective. In: Ganz PA, ed. Cancer Survivorship: Today and Tomorrow. New York, NY: Springer; 2007: 1–7.
   Google Scholar
• Institutes of Medicine. From Cancer Patient to Cancer Survivor. Lost in Transition. Greenfield S, Stovall E, Hewitt M, eds. Washington, DC: The National Academies Press; 2006.
   Google Scholar
• The Nation's Investment in Cancer Research: An Annual Plan and Budget Proposal for Fiscal Year 2009. National Cancer Institute, 2008.
   Google Scholar
• American Society of Clinical Oncology. Clinical practice guidelines. http://www.asco.org/Guidelines. Accessed August 13, 2009.
   Google Scholar
• National Comprehensive Cancer Network. Clinical practice guidelines in oncology, http://www.nccn.org/professionals/physician_gls/default.asp. Accessed August 13, 2009.
   Google Scholar
• Earle CC. Cancer survivorship research and guidelines: maybe the cart should be beside the horse. J Clin Oncol. 2007; 25(25): 3800–3801.
   PubMedGoogle Scholar
• Stein KD, Syrjala KL, Andrykowski MA. Physical and psychological long-term and late effects of cancer. Cancer. 2008; 112(11 suppl): 2577–2592.
   PubMed Web of Science ®Google Scholar
• Carver JR, Shapiro CL, Ng A, et al; ASCO Cancer Survivorship Expert Panel. ASCO Clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007; 25(25): 3991–4008.
   PubMed Web of Science ®Google Scholar
• Landier W, Bhatia S, Eshelman D, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group long-term follow-up guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol. 2004; 22(24): 4979–4990.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Community Cancer Centers Program: Program Summary. http://ncccp.cancer.gov/About/ProgramSummary.htm. Accessed July 13, 2009.
   Google Scholar
• Earle CC, Schrag D, Woolf SH, Ganz PA. The survivorship care plan: what, why, how, and for whom. In: Ganz PA, ed. Cancer Survivorship: Today and Tomorrow. New York, NY: Springer; 2007: 287–293.
   Google Scholar
• Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R. Health profiles in 5836 long-term cancer survivors. Int J Cancer. 2003; 104(4): 488–495.
   PubMed Web of Science ®Google Scholar
• Aziz NM. Late effects of cancer treatments. In: Ganz PA, ed. Cancer Survivorship: Today and Tomorrow. New York, NY: Springer; 2007: 54–76.
   Google Scholar
• National Cancer Institute Office of Cancer Survivorship. Cancer Survivorship Research, http://cancercontrol.cancer.gov/ocs/about.html. Accessed October 15, 2009.
   Google Scholar
• Smith T, Stein KD, Mehta CC, et al. The rationale, design, and implementation of the American Cancer Society's studies of cancer survivors. Cancer. 2007; 109(1): 1–12.
   PubMed Web of Science ®Google Scholar
• Blanchard CM, Coumeya KS, Stein K; American Cancer Society's SCS-II. Cancer survivors' adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society's SCS-II. J Clin Oncol. 2008; 26(13): 2198–2204.
   PubMed Web of Science ®Google Scholar
• McInnes DK, Cleary PD, Stein KD, Ding L, Mehta CC, Ayanian JZ. Perceptions of cancer-related information among cancer survivors: a report from the American Cancer Society's studies of cancer survivors. Cancer. 2008; 113(6): 1471–1479.
   PubMedGoogle Scholar
• Institutes of Medicine. Implementing Cancer Survivorship Care Planning: Workshop Summary. Hewitt M, Ganz P, eds. Washington, DC: The National Academies Press; 2007.
   Google Scholar
• LiveStrong Care Plan, http://www.livestrongcareplan.org. Accessed October 13, 2009.
   Google Scholar
• Journey Forward Survivorship Care Plan Builder. http://www.joumeyforward.org/professionals/survivorship-care-plan-builder.htm. Accessed October 13, 2009.
   Google Scholar
• ASCO Cancer Treatment Summaries, http://www.cancer.net/patient/Survivorship/ASCO+Cancer+Treatment+Summaries. Accessed October 13,2009.
   Google Scholar
• Haylock PJ, Mitchell SA, Cox T, Temple SV, Curtiss CP. The cancer survivor's prescription for living. AJN. 2007; 107(4): 58–70.
   PubMedGoogle Scholar
• Memorial Sloan Kettering Summary of Treatment and Follow-Up Plan. http://www.mskcc.org/mskcc/shared/graphics/Living_Beyond_Cancer/Care_Plan_Vs2.doc. Accessed October 13,2009.
   Google Scholar
• NCI Community Cancer Centers Program. Breast Cancer Survivorship Care Plan. http://ncccp.cancer.gov/NCCCP-ASCO-Breast-Cancer-Survivorship-Care-Plan.pdf. Accessed October 13, 2009.
   Google Scholar
• South Georgia Medical Center. Pearlman Survivorship Care Plan, http://www.sgmc.org/body,cfm?id=652. Accessed October 13, 2009.
   Google Scholar
• Rademaker-Lakhai JM, Crul M, Zuur L, et al. Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol. 2006; 24(6): 918–924.
   PubMed Web of Science ®Google Scholar
• Helson L, Okonkwo E, Anton L, Cvitkovic E. Cis-platinum ototoxicity. Clin Toxicol. 1978; 13(4): 469–478.
   PubMed Web of Science ®Google Scholar
• Kopelman J, Budnick AS, Sessions RB, Kramer MB, Wong GY. Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope. 1988; 98(8 pt 1): 858–864.
   PubMed Web of Science ®Google Scholar
• Gratton MA, Smyth BJ. Ototoxicity of platinum compounds. In: Roland PS, Rutka JA, eds. Ototoxicity. Ontario, Canada: BC Decker; 2004: 60–75.
   Google Scholar
• Moroso MJ, Blair RL. A review of cis-platinum ototoxicity. J Otolaryngol. 1983; 12(6): 365–369.
   PubMedGoogle Scholar
• Park MJ, Park YH, Ahn HJ, et al. Secondary hematological malignancies after breast cancer chemotherapy. Leuk Lymphoma. 2005; 46(8): 1183–1188.
   PubMed Web of Science ®Google Scholar
• Weldon CB, Jaffe BM, Kahn MJ. Therapy-induced leukemias and myelodysplastic syndromes after breast cancer treatment: an underemphasized clinical problem. Ann Surg Oncol. 2002; 9(8): 738–744.
   PubMedGoogle Scholar
• Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol. 1998; 124(3–4): 207–214.
   PubMedGoogle Scholar
• Travis LB, Hodgson D, Allan JM, Van Leeuwen FE. Second cancers. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott, Williams & Wilkins; 2008: 2718–2743.
   Google Scholar
• Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers, version 3.0. www.survivorshipguidelines.org. Accessed July 14, 2009.
   Google Scholar
• Tsao AS, Stewart DJ. Collateral damage associated with chemotherapy. In: Yeung SJ, Escalante CP, Gagel RF, eds. Medical Care of the Cancer Patient. Shelton, CT: People's Medical Publishing House; 2009: 18–32.
   Google Scholar
• Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000; 18(8): 1725–1732.
   PubMedGoogle Scholar
• Courneya KS, Mackey JR, Bell GJ, Jones LW, Field CJ, Fairey AS. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin Oncol. 2003; 21(9): 1660–1668.
   PubMed Web of Science ®Google Scholar
• Cramp F, Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 2008; (2): CD006145.
   Google Scholar
• McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR, Coumeya KS. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ. 2006; 175(1): 34–41.
   PubMed Web of Science ®Google Scholar
• Blackhall L, Petroni G, Shu J, Baum L, Farace E. A pilot study evaluating the safety and efficacy of modafinil for cancer-related fatigue. J Palliat Med. 2009; 12(5): 433–439.
   PubMedGoogle Scholar
• Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr. 2001; (30): 135–142.
   Google Scholar
• Goodwin PJ, Ennis M, Pritchard KI, et al. Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol. 1999; 17(1): 120–129.
   PubMed Web of Science ®Google Scholar
• Demark-Wahnefried W, Peterson BL, Winer EP, et al. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2001; 19(9): 2381–2389.
   PubMed Web of Science ®Google Scholar
• Camoriano JK, Lorprinzi CL, Ingle JN, Themeau TM, Krook JE, Veeder MH. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol. 1990; 8(8): 1327–1334.
   PubMed Web of Science ®Google Scholar
• Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. 2005; 23(7): 1370–1378.
   PubMed Web of Science ®Google Scholar
• Rock CL, Demark-Wahnefried W. Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol. 2002; 20(15): 3302–3316.
   PubMedGoogle Scholar
• Meyerhardt JA, Giovannucci EL, Homes MD, et al. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol. 2006; 24(22): 3527–3534.
   PubMed Web of Science ®Google Scholar
• Doyle C, Kushi LH, Byers T, et al. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin. 2006; 56(6): 323–353.
   PubMed Web of Science ®Google Scholar
• Mehta RS, Chwistek M. Bisphosphonates and osteonecrosis of the jaw #196. J Palliat Med. 2008; 11 (7): 1039–1040.
   PubMedGoogle Scholar
• Shenker NG, Jawad AS. Bisphosphonates and osteonecrosis of the jaw. Rheumatology (Oxford). 2007; 46(7): 1049–1051.
   PubMedGoogle Scholar
• Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999; 17(8): 2365–2370.
   PubMed Web of Science ®Google Scholar
• Frumovitz M, Slomovitz BM, Bodurka DC. Obstetric and gynecologic issues. In: Yeung SJ, Escalante CP, Gagel RF, eds. Medical Care of the Cancer Patient. Shelton, CT: People's Medical Publishing House; 2009: 641–646.
   Google Scholar
• O'Shaughnessy IM, Jochen AL. Metabolic disorders in the cancer patient. In: Berger AM, Shuster JL, Von Roenn JH, eds. Principles and Practice of Palliative Care and Supportive Oncology. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006: 391–399.
   Google Scholar
• Oyer DS, Shah A, Bettenhausen S. How to manage steroid diabetes in the patient with cancer. J Support Oncol. 2006; 4(9): 479–483.
   PubMedGoogle Scholar
• King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist. 2001; 6(2): 162–176.
   PubMed Web of Science ®Google Scholar
• Tichelli A, Socié G. Considerations for adult cancer survivors. Hematology Am Soc Hematol Educ Program. 2005: 516–522.
   Google Scholar
• Mullen JR, Abdalla EK. Hepatobiliary and pancreatic disorders. In: Yeung SJ, Escalante CP, Gagel RF, eds. Medical Care of the Cancer Patient. Shelton, CT: People's Medical Publishing House; 2009: 258–266.
   Google Scholar
• Strieker CT, Jacobs LA. Physical late effects in adult cancer survivors. Oncology Nurse Edition. 2008; 22(8): 33–42.
   Google Scholar
• Shahab I, Patterson WP. Renal and electrolyte abnormalities due to chemotherapy. In: Perry MC, ed. The Chemotherapy Sourcebook. Philadelphia, PA: Lippincott, Williams & Wilkins; 2007: 223–233.
   Google Scholar
• Loescher LJ, Welch-McCaffrey D, Leigh SA, Hoffman B, Meyskens FL. Surviving adult cancers. Part 1: physiologic effects. Ann Intern Med. 1989; 111(5): 411–432.
   PubMed Web of Science ®Google Scholar
• Foringer JR, Finkel KW. Renal failure and renal tubular defects. In: Yeung SJ, Escalante CP, Gagel RF, eds. Medical Care of the Cancer Patient. Shelton, CT: People's Medical Publishing House; 2009: 434–447.
   Google Scholar
• Osanto S, Bukman A, Van Hoek F, Sterk PJ, De Laat JA, Hermans J. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol. 1992; 10(4): 574–579.
   PubMed Web of Science ®Google Scholar
• Stöhr W, Paulides M, Bielack S, et al. Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. Pediatr Blood Cancer. 2007; 48(2): 140–147.
   PubMed Web of Science ®Google Scholar
• Handy BC. Laboratory Investigation. In: Yeung SJ, Escalante CP, Gagel RF, eds. Medical Care of the Cancer Patient. Shelton, CT: People's Medical Publishing House; 2009: 128–132.
   Google Scholar
• Shim K, Mackenzie MJ, Winquist E. Chemotherapy-associated osteonecrosis in cancer patients with solid tumours: a systematic review. DrugSafety. 2008; 31(5): 359–371.
   Google Scholar
• van den Berkmortel F, de Wit R, de Rooy J, DeMulder P. Osteonecrosis in patient with testicular tumours treated with chemotherapy. Neth J Med. 2004; 62(1): 23–26.
   PubMedGoogle Scholar
• Cook AM, Dzik-Jurasz AS, Padhani AR, Norman A, Huddart RA. The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours. Brit J Cancer. 2001; 85(11): 1624–1626.
   PubMedGoogle Scholar
• Engel IA, Straus DJ, Lacher M, Lane J, Smith J. Osteonecrosis in patients with malignant lymphoma: a review of twenty-five cases. Cancer. 1981; 48(5): 1245–1250.
   PubMedGoogle Scholar
• Winquist EW, Bauman GS, Balogh J. Nontraumatic osteonecrosis after chemotherapy for testicular cancer: a systematic review. Am J Clin Oncol. 2001; 24(6): 603–606.
   PubMedGoogle Scholar
• Michaud LB, Goodin S. Cancer-treatment-induced bone loss, part 1. Am J Health-Syst Pharm. 2006; 63(5): 419–430.
   PubMedGoogle Scholar
• Hillner BE, Ingle JN, Chlebowski RT, et al; American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003; 21 (21): 4042–4057.
   PubMed Web of Science ®Google Scholar
• Michaud LB, Goodin S. Cancer-treatment-induced bone loss, part 2. Am J Health-Syst Pharm. 2006; 63(6): 534–546.
   PubMedGoogle Scholar
• Tannock IF, Ahles TA, Ganz PA, van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol. 2004; 22(11): 2233–2239.
   PubMed Web of Science ®Google Scholar
• Kaminski M, Sjogren P. The use of psychostimulants in palliative and supportive treatment of cancer patients. Adv Palliat Med. 2007; 6: 23–31.
   Google Scholar
• Ocean AJ, Vahdat LT. Chemotherapy induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer. 2004; 12(9): 619–625.
   PubMedGoogle Scholar
• Damek DM. Neurologic complications of chemotherapy. In: Yeung SJ, Escalante CP, Gagel RF, eds. Medical Care of the Cancer Patient. Shelton, CT: People's Medical Publishing House; 2009: 387–401.
   Google Scholar
• Maestri A, De Pasquale Ceratti A, Cundari S, Zanna C, Cortesi E, Crinò L. A pilot study on the effect of acetyl-l-camitine in paclitaxel-and cisplatin-induced peripheral neuropathy. Tumori. 2005; 91(2): 135–138.
   PubMed Web of Science ®Google Scholar
• Aksnes LH, Bruland ØS. Some musculoskeletal sequelae in cancer survivors. Acta Oncol. 2007; 46(4): 490–496.
   PubMed Web of Science ®Google Scholar
• Richardson P, Cantwell BM. Autonomic neuropathy after cisplatin based chemotherapy. BMJ. 300(6737): 1466–1467.
   PubMedGoogle Scholar
• Tichelli A, Gratwohl A, Egger T, et al. Cataract formation after bone marrow transplantation. Ann Intern Med. 1993; 119(12): 1175–1180.
   PubMedGoogle Scholar
• Omoti AE, Omoti EC. Ocular toxicity of systemic anticancer chemotherapy. Pharm Prac. 2006; 4(2): 55–59.
   PubMedGoogle Scholar
• Wilding G, Caruso R, Lawrence TS, et al. Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol 1985; 3(12): 1683–1689.
   PubMed Web of Science ®Google Scholar
• Tashiro M, Izumikawa K, Yoshioka D, et al. Lung fibrosis 10 years after cessation of bleomycin therapy. Tohoku J Exp Med. 2008; 216(1): 77–80.
   PubMedGoogle Scholar
• O'Driscoll BR, Hasleton PS, Taylor PM, Poulter LW, Gattameneni HR, Woodcock AA. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med. 1990; 323(6): 378–382.
   PubMedGoogle Scholar
• Bellamy EA, Husband JE, Blaquiere RM, Law MR. Bleomycin-related lung damage: CT evidence. Radiology. 1985; 156(1): 155–158.
   PubMed Web of Science ®Google Scholar
• Murphy WA, Gladish GW, Gupta S, Kumar AJ, Matamoros A, Wong FC. Imaging. In: Yeung SJ, Escalante CP, Gagel RF, eds. Medical Care of the Cancer Patient. Shelton, CT: People's Medical Publishing House; 2009: 111–125.
   Google Scholar
• Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ. Multiple cancer prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev. 2007; 16(3): 566–571.
   PubMed Web of Science ®Google Scholar
• Metayer C, Curtis RE, Vose J, et al. Myelodysplasie syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood. 2003; 101(5): 2015–2023.
   PubMed Web of Science ®Google Scholar
• Zaknoen SL. Complications of cancer and cancer therapy. In: Stein JH, ed. Internal Medicine. 5th ed. St. Louis, MO: Mosby; 1988: 579–586.
   Google Scholar
• Zablotska LB, Matasar MJ, Neugut AI. Second malignancies after radiation treatment and chemotherapy for primary cancers. In: Ganz PA, ed. Cancer Survivorship: Today and Tomorrow. New York, NY: Springer; 2007: 225–237.
   Google Scholar